Regarding the latter, spatial TME profiling of patients treated with TDxD has recently uncovered how responders were characterized by a higher clustering of cancer cells expressing HER2 when compared to non-responders—in which HER2-expressing cells tended to be located at a great distance from each other [95]. Here, ERBB2 is linked to cancer.